Ledaga (Chlormethine)

Ledaga is an alkylating agent indicated for the management of cutaneous T‑cell lymphoma skin disease.

• Mycosis fungoides (cutaneous T‑cell lymphoma): reduces skin lesions and helps control disease progression.
• Other cutaneous T‑cell lymphoma skin lesions: provides local disease control and symptom relief.
• Cutaneous T‑cell lymphoma (CTCL): improves skin‑related manifestations and may delay need for systemic therapy.

• Chlormethine acts as an alkylating agent that forms covalent cross‑links between DNA strands, thereby inhibiting DNA replication and transcription. This interference with the cell cycle leads to apoptosis of rapidly proliferating malignant T‑cells in the skin, resulting in localized tumor control.

Adverse reactions are primarily localized to the application site, though systemic effects can occur rarely.

Common Side Effects

• Skin irritation: redness and discomfort at the treated area.
• Erythema: localized redness and warmth.
• Pruritus: itching of the application site.
• Burning sensation: transient heat or stinging feeling.
• Dryness: flaking or scaling of the skin.
• Hyperpigmentation: darkening of treated skin.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, hives, or anaphylaxis.
• Ulceration: breakdown of skin leading to open sores.
• Secondary infection: bacterial or fungal infection of compromised skin.
• Systemic absorption: potential bone marrow suppression or hematologic abnormalities.
• Carcinogenic potential: theoretical risk due to DNA alkylation.
• Persistent necrosis: tissue death extending beyond the application site.

Use of Ledaga requires careful patient assessment and monitoring.

• Assess skin integrity: ensure lesions are suitable for topical therapy.
• Avoid mucous membranes: do not apply to eyes, mouth, or genital areas.
• Monitor for infection: watch for signs of bacterial or fungal involvement.
• Use protective gloves: healthcare providers should wear gloves during application.
• Store at room temperature: keep in original container, protect from light and moisture.

Chlormethine may interact with other therapies affecting skin or systemic immune function.

Major Interactions (Avoid)

• Concurrent topical alkylating agents: increased local toxicity.
• Systemic chemotherapy causing myelosuppression: heightened risk of hematologic effects.
• Radiotherapy to the same area: amplified skin damage.

Moderate Interactions (Monitor Closely)

• Potent topical corticosteroids: may reduce chlormethine efficacy.
• Other skin irritants: can exacerbate local reactions.
• Systemic immunosuppressants: increased susceptibility to infection.
• Antifungal or antibacterial creams: may alter absorption profile.